Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study.
J Clin Oncol
; 41(31): 4881-4892, 2023 11 01.
Article
in En
| MEDLINE
| ID: mdl-37531592
ABSTRACT
PURPOSE:
Homoharringtonine (HHT) is commonly used for the treatment of Chinese adult AML, and all-trans retinoic acid (ATRA) has been verified in acute promyelocytic leukemia (APL). However, the efficacy and safety of HHT-based induction therapy have not been confirmed for childhood AML, and ATRA-based treatment has not been evaluated among patients with non-APL AML. PATIENTS ANDMETHODS:
This open-label, multicenter, randomized Chinese Children's Leukemia Group-AML 2015 study was performed across 35 centers in China. Patients with newly diagnosed childhood AML were first randomly assigned to receive an HHT-based (H arm) or etoposide-based (E arm) induction regimen and then randomly allocated to receive cytarabine-based (AC arm) or ATRA-based (AT arm) maintenance therapy. The primary end points were the complete remission (CR) rate after induction therapy, and the secondary end points were the overall survival (OS) and event-free survival (EFS) at 3 years.RESULTS:
We enrolled 1,258 patients, of whom 1,253 were included in the intent-to-treat analysis. The overall CR rate was significantly higher in the H arm than in the E arm (79.9% v 73.9%, P = .014). According to the intention-to-treat analysis, the 3-year OS was 69.2% (95% CI, 65.1 to 72.9) in the H arm and 62.8% (95% CI, 58.7 to 66.6) in the E arm (P = .025); the 3-year EFS was 61.1% (95% CI, 56.8 to 65.0) in the H arm and 53.4% (95% CI, 49.2 to 57.3) in the E arm (P = .022). Among the per-protocol population, who received maintenance therapy, the 3-year EFS did not differ significantly across the four arms (H + AT arm 70.7%, 95% CI, 61.1 to 78.3; H + AC arm 74.8%, 95% CI, 67.0 to 81.0, P = .933; E + AC arm 72.9%, 95% CI, 65.1 to 79.2, P = .789; E + AT arm 66.2%, 95% CI, 56.8 to 74.0, P = .336).CONCLUSION:
HHT is an alternative combination regimen for childhood AML. The effects of ATRA-based maintenance are comparable with those of cytarabine-based maintenance therapy.
Full text:
1
Database:
MEDLINE
Main subject:
Leukemia, Promyelocytic, Acute
/
East Asian People
Type of study:
Clinical_trials
/
Guideline
Limits:
Child
/
Humans
Language:
En
Journal:
J Clin Oncol
Year:
2023
Type:
Article
Affiliation country:
China